Pyrazolobenzamide Factor Xa Inhibitors Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current factor Xa inhibitors for treating thromboembolic disorders have limitations in terms of selectivity, pharmacological characteristics, and side effects, necessitating the development of new compounds with improved efficacy and safety profiles.
Innovation Solution
Development of novel pyrazolobenzamide compounds and their derivatives that act as specific inhibitors of factor Xa, offering enhanced therapeutic effects and reduced adverse interactions by modulating their chemical structure to improve pharmacokinetic properties and selectivity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current factor Xa inhibitors are used to treat thromboembolic disorders, then anticoagulant effect is achieved, but selectivity for factor Xa versus other serine proteases is insufficient and side effects occur
Solution Approach 1:
The patent applies local quality by designing the pyrazolobenzamide molecule with specific functional groups at different positions to interact with distinct regions of the factor Xa active site. The benzamide moiety targets the oxyanion hole, while the pyrazole ring and substituent groups (R1-R6) engage with specific hydrophobic pockets and catalytic residues, creating highly localized interactions that enhance selectivity for factor Xa over other serine proteases like trypsin and thrombin.
Solution Approach 2:
The patent employs parameter changes by systematically varying the chemical structure of the pyrazolobenzamide core through different substituents at positions R1-R6. These structural modifications alter the pharmacokinetic parameters (absorption, distribution, metabolism, excretion) and pharmacodynamic parameters (binding affinity, inhibitory potency) to optimize both efficacy and selectivity while minimizing off-target effects and adverse reactions.
2Reliability
If factor Xa inhibition is enhanced to improve therapeutic efficacy, then anticoagulant activity increases, but pharmacological characteristics and safety profile deteriorate
Solution Approach 1:
The patent applies partial action by designing the pyrazolobenzamide inhibitor to bind with high affinity to the factor Xa active site, occupying only the necessary space required for inhibition without excessive bulk. The molecular structure is optimized to achieve potent anticoagulant activity through precise positioning of key pharmacophoric elements, avoiding overly complex or large molecular structures that could increase metabolic burden and adverse interactions.
3Reliability
If new pyrazolobenzamide compounds are developed to improve selectivity and safety, then factor Xa inhibitory activity and selectivity are enhanced, but pharmaceutical development complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the pyrazolobenzamide molecule into distinct functional segments: the core pyrazolobenzamide scaffold, the benzamide group, the pyrazole ring, and various substituent positions (R1-R6). This modular structure allows systematic optimization of each segment's contribution to binding affinity and selectivity, simplifying the drug development process through structure-activity relationship (SAR) analysis of individual segments rather than treating the entire molecule as an indivisible unit.
Data Source
AI summary
The present application describes pyrazolobenzamides and derivatives thereof of Formula I:P4-P-M-M4Ior pharmaceutically acceptable salt forms thereof. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.